STK16-IN-1

Research use only, not for human use.

STK16-IN-1 is an inhibitor of STK16 kinase (IC50: 295 nM).

STK16-IN-1 is an inhibitor of STK16 kinase (IC50: 295 nM).

STK16-IN-1, which exhibits potent inhibitory activity against STK16 kinase (IC50=0.295 μM) with excellent selective across the kinome as assessed using the KinomeScanTM profiling assay. STK16-IN-1 inhibits mTOR kinase with an IC50 of 5.56 μM. In MCF-7 cells, treatment with STK16-IN-1 results in a reduction in cell number and accumulation of binucleated cells, which can be recapitulated by RNAi knockdown of STK16. Co-treatment of STK16-IN-1 with chemotherapeutics such as cisplatin, doxorubicin, colchicine and paclitaxel results in a slight potentiation of the anti-proliferative effects of the chemotherapeutics. STK16-IN-1 provides a useful tool compound for further elucidating the biological functions of STK16).

——

——

Others

Other Targets

STK16

——

——

1223001-53-3

293.3

C17H12FN3O

>98% (HPLC)

DMSO:15 mg/mL (51.14 mM; Need ultrasonic and warming)

CC1=C(C=CC(=C1)N2C(=O)C=CC3=CN=C4C(=C32)C=CN4)F

——

(-20℃)

With Ice Pack

≥ 2 years